Somatic Mutations of the PPP2R1B Candidate Tumor Suppressor Gene at Chromosome 11q23 are Infrequent in Ovarian Carcinomas

Neoplasia

Volumn 1, Issue 4, 1999, Pages 311-314

  Wu, Rong ^a   Connolly, Denise C ^a   Ren, Xiaodan ^a   Fearon, Eric R ^a   Cho, Kathleen H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Human chromosome 11; Loss of heterozygosity; Ovarian carcinoma; PPP2R1B; Tumor suppressor gene

Indexed keywords

ALLELE; ARTICLE; CELL CULTURE; CHROMOSOME 11; CHROMOSOME 17; FEMALE; GENETIC MARKER; GENETICS; HETEROZYGOSITY LOSS; HUMAN; MUTATION; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; OVARY TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ALLELES; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; OPEN READING FRAMES; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0033205655     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900042     Document Type: Article

References (24)

1. Fearon ER (1998). Tumor suppressor genes, in: Vogelstein B, and Kinzler, KW (Eds.), The Genetic Basis of Human Cancer. McGraw-Hill, New York, pp. 229-240.
2. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, Parkin DE, and Haites NE (1993). p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53, 2128-2132.
3. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, and Berchuck A (1991). Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51, 2979-2984.
4. Fujita M, Enomoto T, Inoue M, Tanizawa O, Ozaki M, Rice JM, and Nomura T (1994). Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 85, 1247-1256.
5. Foulkes WD, Campbell IG, Stamp GW, and Trowsdale J (1993). Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer 67, 268-273.
6. Gabra H, Taylor L, Cohen BB, Lessels A, Eccles DM, Leonard RC, Smyth JF, and Steel CM (1995). Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br J Cancer 72, 367-375.
7. Davis M, Hitchcock A, Foulkes WD, and Campbell IG (1996). Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 56, 741-744.
8. Launonen V, Stenback F, Puistola U, Bloigu R, Huusko P, Kytola S, Kauppila A, and Winqvist R (1998). Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions. Gynecol Oncol 71, 299-304.
9. Baysal BE, Farr JE, Goss JR, Devlin B, and Richard CW (1998). Genomic organization and precise physical location of protein phosphatase 2A regulatory subunit A beta isoform gene on chromosome band 11q23. Gene 217, 107-116.
10. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J, and Evans GA (1998). Alterations of the PPP2R1B gene in human lung and colon cancer. Science 282, 284-287.
11. Lee TH, Solomon MJ, Mumby MC, and Kirschner MW (1991). INH, a negative regulator of MPF, is a form of protein phosphatase 2A. Cell 64, 415-423.
12. Li H, Zhao LL, Funder JW, and Liu JP (1997). Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem 272, 16729-16732.
13. Tsao SW, Mok CH, Oike K, Muto MG, Goodman HM, Sheets EE, Berkowitz RS, Knapp RC, and Lau CC (1991). Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors. Anticancer Res 11, 1975-1982.
14. Eccles DM, Cranston G, Steel CM, Nakamura Y, and Leonard RC (1990). Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene 5, 1599-1601.
15. Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT, and Blick M (1990). Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res 50, 2724-2728.
16. Cliby WA, Ritland SR, Hartmann LC, Dodson MK, Hailing KC, Keeney GL, Podratz KC, and Jenkins RB (1993). Human epithelial ovarian cancer allelotype. Cancer Res 53, 2393-2398.
17. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, and Srivastava S (1998). A National Cancer Institute Workshop on Microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58, 5248-5257.
18. Fujita M, Enomoto T, Yoshino K, Nomura T, Buzard GS, Inoue M, and Okudaira Y (1995). Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer 64, 361-366.
19. Thompson FH, Emerson J, Alberts D, Liu Y, Guan XY, Burgess A, Fox S, Taetle R, Weinstein R, Makar R, Powell D, and Trent J (1994). Clonal chromosome abnormalities in 54 cases of ovarian carcinoma. Cancer Genet Cytogenet 73, 33-45.
20. Tapper J, Butzow R, Wahlstrom T, Seppala M, and Knuutila S (1997). Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br J Cancer 75, 1782-1787.
21. Saretzki G, Hoffmann U, Rohlke P, Psille R, Gaigal T, Keller G, Hofler H, Loning T, Petersen I, and Dietel M (1997). Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer 80, 1241-1249.
22. Ichikawa Y, Nishida M, Suzuki H, Yoshida S, Tsunoda H, Kubo T, Uchida K, and Miwa M (1994). Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 54, 33-35.
23. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, and Rice JM (1998). K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139, 777-785.
24. Palacios J, and Gamallo C (1998). Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 58, 1344-1347.